EMA/PE/0000181238 - paediatric investigation plan

resiquimod

Key facts

• Active substance:
  resiquimod
• Therapeutic area:
  Neoplasms benign, malignant and unspecified (incl cysts and polyps)
• Decision number:
  EMA/PE/0000181238
• PIP number:
  EMA/PE/0000181238
• Pharmaceutical form(s):
  Solution for infusion
• Condition(s) / indication(s):
  Treatment of melanoma
• Route(s) of administration:
  Intravenous use
• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  06/12/2024
• Compliance check done:
  No

Decision

EMA/PE/0000181238: EMA decision of 6 December 2024 on the agreement of a paediatric investigation plan and on the granting of a waiver for resiquimod

Adopted Reference Number: EMADOC-1700519818-1775491